Literature DB >> 2575741

CD 15 antigen in Hodgkin's disease.

T Petrella1, J F Michiels, R Michiels, F Collin, J M Nabholtz, S Friedman, P Fargeot.   

Abstract

A retrospective analysis of 117 cases of Hodgkin's disease treated at the Centre G.F. Leclerc between 1976 and 1985 was performed with three objectives: 1): to re-evaluate the histologic subtype by the Lukes-Rye classification according to recent data; 2): to demonstrate the frequency of CD 15 antigen by an indirect, three stage immunoperoxidase technique on initial node biopsy histologic sections; 3): to study the prognostic value of this antigen. Histologic reclassification disclosed that 9 cases were in fact non Hodgkin's lymphoma. The remaining 108 cases were classified as lymphocyte predominant (n = 11), nodular sclerosis (n = 77), and mixed cellularity (n = 17), with no cases of either lymphocyte depletion or nodular paragranuloma of Poppema and Lennert identified. In these specimens, fixed in Bouin's solution and embedded in paraffin, CD 15 antigen was detected in the Reed-Sternberg cells and the mononuclear variety of Hodgkin cells in 64 patients (59%). The presence of this antigen was independent of histologic subtype, patient age or sex, clinical stage and the presence of systemic symptoms. Both actuarial disease-free and overall survivals showed that the prognosis of Hodgkin's disease is more favorable in CD 15 positive cases.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2575741     DOI: 10.1016/S0344-0338(89)80291-2

Source DB:  PubMed          Journal:  Pathol Res Pract        ISSN: 0344-0338            Impact factor:   3.250


  3 in total

1.  Classical Hodgkin's disease. Clinical impact of the immunophenotype.

Authors:  R von Wasielewski; M Mengel; R Fischer; M L Hansmann; K Hübner; J Franklin; H Tesch; U Paulus; M Werner; V Diehl; A Georgii
Journal:  Am J Pathol       Date:  1997-10       Impact factor: 4.307

2.  Relationship of CD15 immunoreactivity and prognosis in sporadic medullary thyroid carcinoma.

Authors:  N Neuhold; F Längle; M Gnant; U Hollenstein; B Niederle
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

3.  Potential for subsets of wt-NPM1 primary AML blasts to respond to retinoic acid treatment.

Authors:  Rodica P Bunaciu; Robert J MacDonald; Feng Gao; Lynn M Johnson; Jeffrey D Varner; Xin Wang; Sarah Nataraj; Monica L Guzman; Andrew Yen
Journal:  Oncotarget       Date:  2017-12-23
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.